Pharmacology, Toxicology and Pharmaceutical Science
Ipilimumab
100%
Nivolumab
100%
Metastatic Melanoma
91%
Progression Free Survival
68%
Adverse Event
57%
Breast Cancer
51%
Neoplasm
51%
Melanoma
48%
Immunotherapy
45%
Epirubicin
42%
Metastatic Breast Cancer
42%
Capecitabine
42%
Vinorelbine
42%
Fulvestrant
42%
Circulating Tumor DNA
42%
Overall Survival
34%
Cytokine
24%
Pembrolizumab
18%
Tumor Necrosis Factor
12%
Breast Tumor
8%
Disease
8%
Anthracycline
8%
Metastasis
8%
Clinical Trial
8%
Prospective Study
8%
Combination Therapy
8%
Formaldehyde
8%
Trametinib
7%
Dabrafenib
7%
Biological Marker
6%
Long Term Survival
6%
Malignant Neoplasm
6%
Medicine and Dentistry
Ipilimumab
57%
Nodular Melanoma
48%
Metastatic Melanoma
48%
Neoplasm
47%
Breast Cancer
42%
Fulvestrant
42%
Circulating Tumor DNA
42%
Nivolumab
42%
Progression Free Survival
42%
Immunotherapy
36%
Drug Response
28%
Biopsy
20%
Cytokine
18%
Pembrolizumab
18%
DNA Determination
12%
Tumor Necrosis Factor
12%
Programmed Death-Ligand 1
12%
Treatment Response
12%
Combination Therapy
9%
Monotherapy
9%
Hormone Therapy
9%
Trametinib
7%
Malignant Neoplasm
6%
Biological Marker
6%
Inflammatory Cytokine
6%
Target Lesion
6%
Long Term Survival
6%
Oncology
6%
Liquid Biopsy
6%
Keyphrases
Tumor-agnostic
42%
Immune-related Adverse Events
42%
Fulvestrant
42%
Multigene Expression
42%
Nivolumab Plus Ipilimumab
42%
Metronomic Therapy
42%
Xena
42%
Soluble PD-L1 (sPD-L1)
42%
Nivolumab
21%
CXCL5
18%
Trametinib
10%
Dabrafenib
10%
Checkpoint Inhibitors
10%
Clinical Benefit Rate
8%
Checkpoint Immunotherapy
6%
Unsupervised Machine Learning Approach
6%
Projection Analysis
6%
Approximation Analysis
6%
